Gfra2 as a candidate immunotherapeutic target in neuroblastoma and ewing sarcoma

A humanized antibody, wherein the antibody binds to GDNF family receptor alpha 2 (GFRA2) and comprises one or more of the following complementarity determining regions (CDRs):

• KSSQSLLDTDGKTYLN (SEQ ID NO:
• 15) or a sequence with at least 95% sequence identity to SEQ ID NO:
• 15,
• LVSKLDS (SEQ ID NO:
• 16) or a sequence with at least 95% sequence identity to SEQ ID NO:
• 16,
• WQGTHFPQT (SEQ ID NO:
• 17) or a sequence with at least 95% sequence identity to SEQ ID NO:
• 17,
• GYFMH (SEQ ID NO:
• 18) or a sequence with at least 95% sequence identity to SEQ ID NO:
• 18,
• RINPYNGATNYNQIFKD (SEQ ID NO:
• 19) or a sequence with at least 95% sequence identity to SEQ ID NO:
• 19,
• GGHYYGNVDY (SEQ ID NO:
• 20) or a sequence with at least 95% sequence identity to SEQ ID NO:
• 20,
• GYSFTGY (SEQ ID NO:
• 21) or a sequence with at least 95% sequence identity to SEQ ID NO:
• 21, and
• NPYNGA (SEQ ID NO:
• 22) or a sequence with at least 95% sequence identity to SEQ ID NO:
• 22.